Christina Rossi Sells 2,274 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now owns 71,657 shares of the company’s stock, valued at approximately $6,814,580.70. This represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Blueprint Medicines Stock Performance

BPMC stock opened at $96.53 on Wednesday. The company’s 50 day simple moving average is $91.12 and its 200-day simple moving average is $97.97. Blueprint Medicines Co. has a 52-week low of $70.39 and a 52-week high of $121.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company’s revenue was up 126.5% on a year-over-year basis. During the same period in the previous year, the business earned ($2.20) EPS. On average, equities research analysts anticipate that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On Blueprint Medicines

A number of institutional investors have recently bought and sold shares of BPMC. Franklin Resources Inc. increased its holdings in shares of Blueprint Medicines by 0.7% in the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock valued at $3,259,000 after purchasing an additional 265 shares during the period. Synovus Financial Corp increased its stake in Blueprint Medicines by 4.0% in the 3rd quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company’s stock valued at $2,224,000 after buying an additional 922 shares during the period. Sanctuary Advisors LLC purchased a new stake in Blueprint Medicines in the 3rd quarter worth approximately $202,000. Teachers Retirement System of The State of Kentucky boosted its stake in shares of Blueprint Medicines by 23.7% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 16,520 shares of the biotechnology company’s stock valued at $1,528,000 after buying an additional 3,162 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Blueprint Medicines by 1.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company’s stock valued at $136,942,000 after acquiring an additional 20,703 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on BPMC. HC Wainwright reissued a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. JMP Securities reissued a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Monday, November 18th. Wedbush reaffirmed an “outperform” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Thursday, November 14th. JPMorgan Chase & Co. initiated coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They set an “overweight” rating and a $126.00 price objective on the stock. Finally, Wells Fargo & Company cut their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $122.11.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.